Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Vivani Medical ( (VANI) ) just unveiled an update.
On June 10, 2025, Brigid Makes announced her resignation as Chief Financial Officer of Vivani Medical, effective June 15, 2025, with no disagreements cited with the company. Subsequently, on June 11, 2025, Vivani Medical appointed Anthony Baldor as the new Chief Financial Officer, effective June 15, 2025. Baldor brings over 20 years of experience in financial management within the biotechnology sector, having previously held significant roles at Diakonos Oncology Corp. and 4D Molecular Therapeutics, Inc. His expertise is expected to be instrumental in advancing Vivani’s pipeline and scaling its operations, marking a pivotal time for the company.
The most recent analyst rating on (VANI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Vivani Medical stock, see the VANI Stock Forecast page.
Spark’s Take on VANI Stock
According to Spark, TipRanks’ AI Analyst, VANI is a Neutral.
Vivani Medical’s overall score reflects its challenging financial situation and unfavorable valuation. Despite some positive corporate events and neutral technical indicators, the company’s consistent losses and reliance on external financing weigh heavily on the score. The strategic focus on core drug implant business and recent milestones offer some potential for improvement, but substantial operational and financial efficiency improvements are necessary for a stronger outlook.
To see Spark’s full report on VANI stock, click here.
More about Vivani Medical
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that specializes in developing miniature, ultra long-acting drug implants using its proprietary NanoPortal™ platform. The company’s lead program, NPM-115, is a six-month, subdermal GLP-1 implant for chronic weight management, and it is also developing other implants for weight management and type 2 diabetes treatment.
Average Trading Volume: 90,903
Technical Sentiment Signal: Sell
Current Market Cap: $69.32M
For detailed information about VANI stock, go to TipRanks’ Stock Analysis page.